Lexeo Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LXEO research report →
Price Chart
About the company
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates.
- CEO
- R. Nolan Townsend
- IPO
- 2023
- Employees
- 59
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on LXEO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $397.32M
- P/E
- -4.40
- Fwd P/E
- 8.96
- PEG
- -0.04
- P/S
- 0.00
- P/B
- 1.84
- EV/EBITDA
- -3.64
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.85%
- ROIC
- -39.33%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-109,257,000
- Net Income
- $-99,961,000-1.7%
- EPS
- $-1.86+39.8%
- OCF Growth
- -21.5%
- FCF Growth
- -21.2%
- 52W High
- $10.99
- 52W Low
- $3.99
- 50D MA
- $4.68
- 200D MA
- $6.63
- Beta
- 1.47
- RSI (14)
- 57
- Avg Volume
- 924.86K
No earnings-call transcripts are available for LXEO yet.
- Free Float
- 60.4%
- Shares Outstanding
- 78.52M
- Float Shares
- 47.42M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 26 | Tamayo Louis Edward | sell | 4,117 |
| Aug 18, 26 | Townsend Richard Nolan | sell | 3,345 |
| Aug 18, 26 | Otero Jose Manuel | sell | 1,304 |
| Jun 29, 26 | Tamayo Louis Edward | other | 12,000 |
| Jul 1, 26 | Tamayo Louis Edward | sell | 4,641 |
| Jun 29, 26 | Otero Jose Manuel | other | 12,060 |
| Jul 1, 26 | Otero Jose Manuel | sell | 4,666 |
| Jun 29, 26 | Bhalla Narinder Pal | other | 55,000 |
| Jul 1, 26 | Bhalla Narinder Pal | sell | 22,306 |
| Jun 29, 26 | Townsend Richard Nolan | other | 67,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LXEO coverage
Recent articles, reports, and earnings notes.
No research on LXEO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LXEO report →